Although Rev and Dex are a common drug combination in MM therapy [110,111], early studies showed that the NK-mediated killing of MM cells enhanced in the presence of Rev and CD4+ T cells was abrogated by the addition of Dex [112,113]. The gene discussed is CD4; the disease is Miyoshi myopathy.